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Abstract
Background: T follicular helper (Tfh) cells have been identified as a new category of helper T cells, which express
CXCR5 on their surface and induce the production of antigen-specific antibodies. Many investigations have found
morbid proliferation and/or activation of Tfh cells in systemic autoimmune and allergic diseases. It is also known
that Tfh cells are regulated by regulatory B (Breg) cells in the deteriorating such diseases. Recently, CXCL13, a ligand
of CXCR5, has been reported to increase in the peripheral blood and lungs of patients with idiopathic pulmonary
fibrosis (IPF). This study aimed to investigate the involvement of Tfh cells and Breg cells in IPF.
Methods: Peripheral blood samples were obtained from 18 patients with IPF. We isolated heparinized
peripheral blood mononuclear cells and investigated the proportions of Breg cells, Tfh cells, PD-1+ICOS+ Tfh
cells (activated form of Tfh cells), and the Tfh-cell subsets by flow cytometry. These cell profiles were
compared with those of 21 healthy controls. Furthermore, we investigated the correlations between profiles
of lymphocytes and lung physiology.
Results: The median proportions of Tfh cells per total CD4+ T cells and of PD-1+ICOS+ proportion of Tfh cells
per total Tfh cells was significantly more in the IPF patients (20.4 and 5.2%, respectively) compared with
healthy controls (15.4 and 2.1%, respectively; p = 0.042 and p = 0.004, respectively). The proportion of Tfh2 cells
per total Tfh cells was significantly higher and the proportion of Tfh17 was smaller in the IPF patients than
healthy controls. The percentage of Breg cells to total B cells was significantly decreased in the IPF patients
(median, 8.5%) compared with that in the controls (median, 19.7%; p < 0.001). The proportion of Breg cells
was positively correlated with the annual relative change in diffusing capacity of the lungs for carbon
monoxide in the IPF patients (r = 0.583, p = 0.018).
Conclusion: Proliferation and activation of Tfh cells and a decrease in Breg cells were observed in the
peripheral blood of patients with IPF. The profile of the Tfh-cell subset also changed. Specific humoral
immunity aberration would likely underlie complicated pathophysiology of IPF.
Keywords: Idiopathic pulmonary fibrosis (IPF), T follicular helper cell (Tfh cell), regulatory B cell (Breg cell),
CXCR5 (C-X-C motif chemokine receptor 5), ICOS (inducible co-stimulatory molecule), PD-1 (programmed
death 1), autoimmunity immunity
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive and
irreversible disease with a median survival time of about
3–5 years after diagnosis [1]. The etiology of IPF is still
enigmatic; however, autoimmunity is considered to
cause the pathogenesis of IPF [2, 3]. This is suggested by
the evidence that the serum and bronchoalveolar lavage
fluid of IPF patients preferentially contain antigen–anti-
body complexes and most patients also carry autoanti-
bodies [4, 5]. Further, a marked correlation between
specific antibodies against autoantigens (e.g., heat shock
protein 70) and symptoms and prognosis of IPF patients
has been demonstrated [6–9]. Recently, it was also found
that IPF patients show an abnormal expression of C-X-C
motif chemokine ligand 13 (CXCL13), which is a critical
chemokine for the homing of B cells and T follicular
helper cells (Tfh cells) to lymphoid tissues as well as in-
flammatory foci [10–12]. There is a strong association
between circulating concentrations of CXCL13 and both
clinical manifestations and disease progression of IPF
[13], whereas immune settings of B cells and Tfh cells in
the pathogenesis of IPF are still ill-defined.
Because B cells have an important role in specific host
defense, their functional alterations cause the onset and
exacerbation of autoimmune and allergic diseases. Re-
cent studies have suggested that regulatory B (Breg) cells
producing interleukin (IL)-10 and transforming growth
factor-beta of a negative regulatory cytokine operate the
production of antibodies in health and diseases [14, 15].
Indeed, the absence or loss of Breg cells exacerbates
disease symptoms in both allergic and autoimmune dis-
eases [15–17]. CD4+ T cells present in B-cell follicles,
known as Tfh cells, have been established as a helper T
(Th)-cell subset specialized in providing help to B cells
in germinal centers (GCs). Tfh cells express the C-X-C
motif chemokine receptor 5 (CXCR5) that is responsible
for their migration into B-cell follicles in response to a
CXCR5-specific ligand, CXCL13. Additionally, Tfh cells ex-
press co-stimulatory molecules, inducible co-stimulatory
molecule (ICOS), immune-regulatory molecules, pro-
grammed death 1 (PD-1), and B-cell lymphoma-6 (BCL6)
as their transcription factors. Tfh cells secrete IL-4, IL-10,
and IL-21; these cytokines promote growth, differentiation,
and class switching of B cells [18–20]; additionally, they are
the most powerful Th cells in inducing antigen-specific
antibody responses. Excessive reaction of Tfh cells causes
autoantibody production, leading to autoimmune disease
[21–23]. It is difficult to repeatedly examine lymphoid tis-
sue in clinical practice; therefore, circulating CXCR5+ Th
cells have been well investigated. CXCR5+ Th cells in the
peripheral blood are reported to be associated with Tfh
cells present in lymphoid tissue [19, 23, 24] and are recog-
nized as memory Tfh cells [20]. Recent findings have clari-
fied the relationship between Breg and Tfh cells, suggesting
that Breg cells suppress Tfh-cell maturation and regulate
antibody production [25].
On the basis of previous studies demonstrating that
the pathogenesis of IPF is involved in autoimmunity, this
study aimed to test the hypothesis that Breg and Tfh
cells were associated with the pathogenesis of IPF.
Methods
Study population
Peripheral blood samples (20 mL) were obtained from
18 patients with IPF who attended the Sapporo Medical
University Hospital from February 1st to September
30th in 2016. The diagnosis of IPF conformed to the
ATS/ERS/JRS/ALAT statement in 2011 [1]. Patients
who were treated with corticosteroids and/or immuno-
suppressive agents were excluded from this study. We
used the data of 21 control subjects without previous
histories of any respiratory diseases, collagen diseases,
rheumatoid arthritis, and allergic diseases to compare
with those of IPF patients. We obtained written in-
formed consent from all the participants. This study was
conducted in accordance with the Declaration of
Helsinki and was approved by the Institutional Review
Board of the Sapporo Medical University School of
Medicine (approval number: 272–94).
Antibodies
Antibodies used in the flow cytometry were anti-CD3-
APC (UCHT1), anti-CD4-APC-Cy7 (RPA-T4), anti-
CXCR5-PerCP-Cy5.5 (RF8B2), anti-PD-1-PE (EH12.1),
and anti-ICOS-BV421 (DX29) in measuring Tfh cells and
PD-1+ICOS+ Tfh cells; anti-CD3-FITC (SK7), anti-CD4-
APC-Cy7 (RPA-T4), anti-CXCR5-PerCP-Cy5.5 (RF8B2),
anti-CXCR3-PE-Cy7 (1C6/CXCR3), anti-CCR6-APC (11A9),
anti-PD-1-PE (EH12.1), and anti-ICOS-BV421 (DX29) in
investigating the Tfh-cell subset; anti-CD19-APC-Cy7
(SJ25C1), anti-CD20-PE (2H7), anti-CD24-PerCP-Cy5.5
(ML5), anti-CD27-FITC (M-T271), and anti-CD38-BV421
(HIT2) in measuring Breg cells, gated by cells negative to
anti-CD3-APC (UCHT1). All antibodies were purchased
from BD Biosciences.
Lymphocyte populations and flow cytometry
We defined CD3+CD4+CXCR5+ lymphocytes as Tfh
cells, including Tfh1 cells (CXCR3+CCR6−), Tfh2 cells
(CXCR3−CCR6−) and Tfh17 cells (CXCR3−CCR6+), and
Breg cells (CD3−CD19+CD24hiCD27+) [18, 26, 27]. PD-
1+ICOS+ Tfh cells were regarded as an activated pheno-
type of Tfh cells [26]. We isolated heparinized peripheral
blood mononuclear cells from fresh blood specimens by
centrifugation over a discontinuous density gradient
(Lympholyte-H; Cedarlane Laboratories Ltd., Canada)
and investigated the proportion of Breg cells (to
CD3−CD19+ B cells), Tfh cells (to CD3+CD4+ T cells),
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PD-1+ICOS+ Tfh cells (to all Tfh cells), and the Tfh-cell
subset by flow cytometry (BD FACSCanto™ II; BD Bio-
sciences, USA). These cell profiles among the IPF pa-
tients and healthy controls were compared by
performing the Wilcoxon test.
Correlation between the profile of lymphocytes and lung
physiology
We examined the results of the pulmonary function test
(PFT) performed within 3 months before or after the day
of blood sampling in the IPF patients and investigated
the correlation between the proportions of Tfh cells,
PD-1+ICOS+ Tfh cells, Tfh-cell subsets, Breg cells, and
the % predicted forced vital capacity (%FVC), % pre-
dicted diffusing capacity of the lungs for carbon monox-
ide (%DLCO) by using the Spearman correlation
method. Regarding patients who had undergone previ-
ous PFT, we converted the change in the FVC and
DLCO into annual relative change (ΔFVC and ΔDLCO)
and investigated the correlation between them and the
profiles of lymphocytes. When we defined FVC at the
time of the cell investigation as FVC2 and FVC in the
previous study as FVC1, the duration between the time
of cell investigation and the previous PFT time given as
X (months), the ΔFVC (%) was calculated by (FVC2 −
FVC1) / FVC2 × 100 × 12 / X. Similarly, when we de-
fined DLCO (mL/min/mmHg) at the time of the cell in-
vestigation as DLCO2 and DLCO in the previous study
as DLCO1, the duration between the time of cell investi-
gation and the previous PFT time given as X (months),
the ΔDLCO (%) was calculated by (DLCO2 −DLCO1) /
DLCO2 × 100 × 12 / X.
Statistics
We used SPSS Statistics 21 (IBM Inc.) for statistical ana-
lysis. In each test, p < 0.05 was regarded as indicative of
statistically significant differences. Data were shown as




The subject characteristics in this study are summarized
in Table 1. We compared the IPF group (14 men and 4
women, mean age; 68.2 ± 7.13 years [range, 50–79 years])
with the healthy group (7 men and 14 women, mean
age; 67.8 ± 9.09 years [range, 57–88 years]). The duration
from the diagnosis of IPF to the time of blood sampling
varied (range, 0–35months), and the median duration
was 17.4 months. The median %FVC and %DLCO of IPF
patients were 91.7% (interquartile range [IQR], 80.1–
101.7%) and 56.7% (IQR, 50.6–66.0%), respectively. Six-
teen patients with IPF had undergone previous PFT. The
median duration between the PFT at the time of the cell
investigation and the previous PFT was 24.5 months
(range, 9.0–39.0 months). The median ΔFVC was −
4.25% (IQR, − 5.33−− 1.78%) and the median ΔDLCO
was − 5.05% (IQR, − 12.88−− 2.70%).
Tfh cells and Tfh-cell subsets
The median proportion of Tfh cells
(CD3+CD4+CXCR5+) to total T cells (CD3+CD4+) was
20.4% (IQR, 13.4–27.2%) in the IPF patients and 15.4%
(IQR, 14.2–19.7%) in the healthy controls and signifi-
cantly higher in the IPF patients (p = 0.042; Fig. 1). Tfh
cells that express the co-stimulated molecules PD-1 and
ICOS are considered to be the activated forms of Tfh
cells. The median proportion of PD-1+ICOS+ Tfh cells
to total Tfh cells in the IPF patients (5.2% [IQR, 2.5–
9.4%]) was also significantly higher than that of the
healthy controls (2.1% [IQR, 1.6–3.6%], p = 0.004; Fig. 2).
According to the expression profiles of two chemokine
receptors, CXCR3 and CCR6, circulating Tfh cells in
blood are classified into three Tfh-cell subsets including
Tfh1 cells, which produces interferon-gamma like Th1
cells; Tfh2, which produces IL-4, IL-5, and IL-13 like Th2
cells; and Tfh17 cells, which produces IL-17 and IL-22 like
Th17 cells. Figure 3 shows the proportions of Tfh1, Tfh2,
and Tfh17 cells to total Tfh cells in the IPF patients and
healthy controls. Figure 3a shows representative profiles
Table 1 Subject characteristics
Patients with IPF (n = 18) Controls (n = 21)
Age (years) (mean ± SD [range]) 68.2 ± 7.1 (50–79) 67.8 ± 9.1 (57–88)
Male/female 14/4 7/14
%FVC (median [IQR]) 91.7 (80.1–101.7) NR
%DLCO (median [IQR]) 56.7 (50.6–66.0) NR
Current or ex-smoker (%) 83.3 47.6
GAP stage (number) I (10), II (6), III (2) NR
6-min walk test distance (m) (median [IQR]) 420 (380–500) (n = 11) NR
Desaturation during 6-min walk test (number) 4 (n = 11) NR
IPF idiopathic pulmonary fibrosis, SD standard deviation, %FVC forced vital capacity % predicted, IQR interquartile range, NR data not reported, %DLCO diffusing
capacity of the lung for carbon monoxide % predicted
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of the flow cytometry of the IPF patients and healthy
controls. The median percentage of Tfh2 cells in the
IPF patients was 41.2% (IQR, 36.5–47.0%), signifi-
cantly higher than that in the controls (median, 33.7%
[IQR, 32.4–36.7%]; Fig. 3c). On the other hand, the
proportion of the Tfh17 subset in the IPF patients
(median, 25.5% [IQR, 20.2–32.8%]) was smaller than
that in the healthy subjects (34.2% [IQR, 32.5–37.4%];
Fig. 3d). The percentage of Tfh1 cells was comparable
between the two groups (Fig. 3b).
Regulatory B cells
The proportion of Breg cells to total B cells (CD3−CD19+)
was significantly decreased in the IPF patients (median,
8.5% [IQR, 6.8–12.2%]) relative to that in the controls
(median, 19.7% [IQR, 13.4–27.2%], p = 0.001; Fig. 4).
Fig. 1 Ratios of circulating total Tfh cells in IPF and healthy cases. a Representative fluorescence-activated cell sorting profiles indicating total Tfh
cells (CD3+CD4+CXCR5+). Plots were pregated on CD3+CD4+ cells and examined by the levels of CXCR5. The numbers indicate the proportion of
cells in the gate. b The proportion of total Tfh cells in CD3+CD4+ cells is shown in the panel. Tfh, follicular helper T; IPF, idiopathic
pulmonary fibrosis
Fig. 2 Ratios of circulating PD1+ICOS+Tfh cells in IPF and healthy cases. a Representative fluorescence-activated cell sorting profiles indicating PD-
1+ICOS+Tfh cells. Plots were pregated on CD3+CD4+CXCR5+ cells and examined by the levels of PD-1 and ICOS. The numbers indicate the
proportion of cells in the gate. b The proportion of PD-1+ICOS+Tfh cells in Tfh cells is shown in the panel. Tfh, follicular helper T; IPF, idiopathic
pulmonary fibrosis
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Correlation between the peripheral blood mononuclear
cells profile and lung function
Tfh-cell profiles (proportion of Tfh and activated Tfh,
Tfh-cell subset) did not correlate with lung function and
the change in lung function. Although the proportion of
Breg cells to CD3−CD19+ cells correlated with neither
%FVC nor %DLCO at the time of blood sampling, a
positive correlation between the proportion of Breg cells
and ΔDLCO was observed (r = 0.583, p = 0.018; Fig. 5).
Discussion
In this study, we first show a possible involvement of
Tfh cells and Breg cells in the pathogenesis of IPF, which
is the most common type of idiopathic interstitial pneu-
monias. Tfh cells share CXCR5 of a chemokine receptor
with B cells and have a strong capacity to evoke antigen-
specific antibody responses by producing IL-21 in large
quantities for the B-cell proliferation and differentiation
[28, 29]. The differentiation and class switching of B
cells are also promoted by the interaction of CD40 and
CD40 ligand, which is presented on Tfh cells. ICOS and
PD-1 as immunoregulatory molecules are highly
expressed on Tfh cells and have an essential role in the
differentiation and activation of Tfh cells to form GCs of
lymphoid follicles. Based on the expression profile of
ICOS and PD-1, circulating Tfh cells are identified as an
active form (PD-1+ICOS+) and an inactive form (PD-
1−ICOS− or PD-1+ICOS−) [26]. In healthy individuals,
most circulating Tfh cells rarely present ICOS and are,
thus, postulated as an inactive form. In contrast, circu-
lating ICOS+ Tfh cells are markedly increased in patients
with autoimmune diseases, including systemic lupus ery-
thematosus, Sjogren’s syndrome, rheumatoid arthritis,
and dermatomyositis [19, 30–34]. Moreover, it is note-
worthy that the proportion of ICOS+ Tfh cells well
correlates with disease activity and autoantibody titer
[19, 30–34]. Here the proportions of Tfh cells and acti-
vated Tfh cells (PD-1+ICOS+ Tfh cells) were significantly
Fig. 3 Polarization of circulating Tfh-cell subsets in IPF and healthy cases. a Representative fluorescence-activated cell sorting profiles indicating
Tfh1 cells (CXCR3+CCR6−), Tfh2 cells (CXCR3−CCR6−), and Tfh17 cells (CXCR3−CCR6+). Plots were pregated on CD3+CD4+CXCR5+ cells and
examined by the levels of CXCR3 and CCR6. The numbers indicate the proportion of cells in the gate. b–d The proportions of Tfh-cell subsets
among all Tfh cells are shown in the panel. b Tfh1 cells, (c) Tfh2 cells and (d) Tfh17 cells. Tfh, follicular helper T; IPF, idiopathic pulmonary fibrosis
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elevated in patients with IPF, suggesting that ICOS+ Tfh
cells underlie pathologic autoimmunity responses of IPF.
Duncan SR et al. have reported that the proportion of
CXCL13 and B-lymphocyte stimulating factor (BLyS) are
significantly increased in lungs and peripheral blood of
patients with IPF and that CXCL13 acts as a prognostic
biomarker of IPF [3, 13]. There is a significant correl-
ation between the plasma level of CXCL13 and GC
activity of lymph nodes in human and mouse because
CXCL13 has a cardinal role to engage Tfh cells and B
cells expressing CXCR5 of a CXCL13 receptor [35].
Therefore, immune settings producing specific anti-
bodies are probably activated in the patients with IPF.
Breg cells suppress the maturation of Tfh cells and a
pathologically low level of Breg cells is observed in vari-
ous immune-related diseases like autoimmune diseases
[36–38] as well as allergic diseases [22, 39]. So far, the
fact that the patients with IPF showed a decreased level
of Breg cells in comparison with healthy controls sug-
gests that a tolerance mechanism mediated by Breg cells
is not fully achieved in the regulation of activated Tfh
cells in the patients with IPF [25].
Alteration of Tfh-cell subsets is observed in various
immune-related diseases. Both Tfh2 cells and Tfh17 cells
are predominant in autoimmune diseases, such as
systemic lupus erythematosus, Sjogren’s syndrome, and
systemic scleroderma [26]. The current study showed
predominance of Tfh2 cells and inferiority of Tfh17 cells
in the patients with IPF. IL-4 and IL-13, which Tfh2 cells
are known to produce, strongly promote fibrosis [40],
implying a possible involvement of Tfh2 cells in the
pathogenesis of IPF. The proportion of Tfh2 cells in-
creases and Tfh1 cells decreases in bronchial asthma
and allergic rhinitis [22]. A different distribution in the
Tfh-cell subsets suggests that autoimmunity is involved
in the pathogenesis of IPF with mechanisms different
from those of autoimmune and allergic diseases.
We examined the relationship between the results of
PFT and Tfh/Breg-cell profiling measured at the same
time. Results indicated that there was a positive
Fig. 4 Proportions of circulating Breg cells in IPF and healthy cases. a Representative fluorescence-activated cell sorting profiles indicating Breg
cells (CD24hiCD27+). Plots were pregated on CD3−CD19+ cells and examined according to the levels of CD24 and CD27. The numbers indicate
the proportion of cells in the gate. b The proportion of Breg cells among all CD3−CD19+ B cells is shown in the panel. Breg, regulatory B; IPF,
idiopathic pulmonary fibrosis
Fig. 5 Correlation between the proportion of Breg cells and ΔDLCO
in patients with idiopathic pulmonary fibrosis. ΔDLCO: means annual
changes in DLCO. Breg: regulatory B; DLCO: diffusing capacity of the
lung for carbon monoxide
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correlation was found between the proportion of Breg
cells and the annual relative change in DLCO (ΔDLCO);
in other words, patients with fewer Breg cells could see
worsening of DLCO. Although annual declines of FVC >
10% and/or DLCO > 15% are regarded as significant
changes in the clinical course of IPF in many studies
[41–43], most patients in this study showed declines
below this threshold, which indicates that the clinical
significance of the change in the proportion of Breg cells
is unknown. Further studies using another IPF cohort
with more severe diseases are necessary to verify this
clinical significance. Moreover, we investigated the
change in pulmonary function going back from the time
of blood sampling, we need to conduct a prospective
study to confirm whether or not the reduction in Breg
cells will be a predictor of the deterioration of DLCO.
The clinical features of IPF patients greatly vary, and
IPF might include multiple subtypes, some of which
have auto-immune features. In this study, we found that
large numbers of patients with IPF displayed increases of
activated Tfh cells and/or decreases of Breg cells in the
peripheral blood. Among these patients, a morbid im-
mune system might play an important role in disease
progression. Measuring the numbers of activated Tfh
cells and Breg cells in the peripheral blood may provide
a useful marker for identifying this subgroup. Anti-
inflammatory therapies, such as corticosteroids, have
been reported to be ineffective for the treatment of IPF
[44]; however, some pulmonary diseases involving auto-
antibodies, such as granulomatosis with polyangitis and
Goodpasture’s syndrome, are also known to be cortico-
steroid resistant [45]. For such diseases, treatment that
suppresses the activation of B cells, such as rituximab, a
human anti-CD20 monoclonal antibody, is sometime ef-
fective [46]. Furthermore, there are reports that treat-
ment to remove autoantibodies is effective for IPF [47];
therefore a new therapeutic approach targeted to Breg
cells and Tfh cells is expected.
There were several limitations in this research. The
number of cases was small; there were only 18 cases of
IPF and 21 cases of healthy subjects. Age was compar-
able among the patients with IPF and the controls; how-
ever, there was a higher proportion of females in the
controls. The effects of gender on the proportions of
Tfh and Breg cells and lymphocyte activation are not
known, and we found no significant differences in these
factors between males and females in the controls of this
study (data not shown). Some issues related to the in-
volvement of Tfh cells and Breg cells in the pathophysi-
ology of IPF remain to be elucidated. First, where is the
field of activity of these cells? Unlike interstitial pneumo-
nia associated with autoimmune disease, morbid prolif-
eration of lymph follicles and lymphocytic infiltration
are generally negative pathological findings of IPF [48].
Since these cells might proliferate and be activated not
in fibrotic lungs of IPF but in regional lymph nodes, fur-
ther studies to investigate lung tissue and lymph nodes
of patients with IPF will be required. As the next step,
we plan to investigate the effects of morbid changes in
the Tfh and Breg cells on pulmonary fibrosis by implant-
ing activated Tfh cells (or Breg cells) into a lung fibrosis
mice model. Moreover, although antigens are essential
for incorporating autoimmunity, antigens in IPF are un-
known. However, various types of autoantibodies have
been reported to be involved in the pathogenesis of IPF,
and the antigens might vary from patient to patient.
Conclusions
In this study, we investigated the involvement of Tfh
cells and Breg cells in IPF, which is fatal and has limited
treatment options. The involvement of autoimmunity in
fibrosis of the IPF lung is thought to be complicated.
The diversity and complexity of the morbid immune set-
tings seems to explain why corticosteroids and/or immu-
nosuppressants are not so effective for IPF. According to
this study, we can expect that drugs targeting Tfh cells
and Breg cells will be developed as a new therapeutic
strategy against IPF.
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